| Literature DB >> 28580733 |
Juan Marquet1, Kyra Velazquez-Kennedy1, Sandra López1, Amparo Benito2, María-Jesús Blanchard3, Jose Antonio Garcia-Vela4.
Abstract
Primary effusion lymphoma is a rare non-Hodgkin lymphoma that presents with pleural effusions and lacking of tumour mass. It is universally associated with human herpesvirus 8 (HHV8) and is more frequent among immunosuppressed patients. There is no standard treatment, chemotherapy and anti-HIV therapy have been used with poor results, but there is still no strong evidence supporting the use of valganciclovir. We present the case of a HIV positive man that presented with pleural effusion compatible with primary effusion lymphoma and positivity for HHV8 DNA in blood. Bortezomib-containing treatment protocol was started, but the disease progressed within the chemotherapy. Therefore, treatment with oral valganciclovir was decided and the patient achieved a sustained radiological complete response. HHV8 DNA turned negative 6 months after starting the treatment with valganciclovir.Entities:
Keywords: Kaposi sarcoma; aggressive lymphoma; human herpesvirus 8; primary effusion lymphoma; valganciclovir
Mesh:
Substances:
Year: 2017 PMID: 28580733 DOI: 10.1002/hon.2445
Source DB: PubMed Journal: Hematol Oncol ISSN: 0278-0232 Impact factor: 5.271